Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) were up 5.7% during trading on Thursday . The company traded as high as $6.99 and last traded at $6.66, with a volume of 651,265 shares changing hands. The stock had previously closed at $6.30.

A number of analysts have recently commented on AVXL shares. FBR & Co started coverage on shares of Anavex Life Sciences Corp. in a report on Tuesday, March 29th. They set an “outperform” rating and a $10.00 target price on the stock. Maxim Group restated a “buy” rating and set a $15.00 target price on shares of Anavex Life Sciences Corp. in a report on Friday, March 25th. Finally, Zacks Investment Research upgraded shares of Anavex Life Sciences Corp. from a “hold” rating to a “buy” rating and set a $5.00 target price on the stock in a report on Tuesday, May 31st.

The company’s 50 day moving average price is $4.78 and its 200 day moving average price is $4.79. The firm’s market cap is $270.68 million.

Anavex Life Sciences Corp. (NASDAQ:AVXL) last released its quarterly earnings results on Wednesday, May 11th. The company reported ($0.06) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.16) by $0.10. On average, equities analysts forecast that Anavex Life Sciences Corp. will post ($0.34) earnings per share for the current year.

Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.